Swirsky Douglas J
Transaction: 05/01/2026
OTHER
Change
0
Price
Not reported
Filing
05/01/2026
Type
OTHER
Barinthus Biotherapeutics plc
BRNS • Biotechnology
$0.76
▲ +0.04 (+5.50%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$31.00M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 275.1%Manageable debt level · 0.15Healthy liquidity · 7.77Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:46 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.76
Change5.50%
Shares Out40.85M
Market Cap$31.00M
Enterprise Value$-28.29M
52W Range0.51 - 1.83
Beta-0.40
P/E-0.74
P/B0.54
P/FCF-1.20
EV/EBITDA0.72
EV/FCF1.09
Price$0.76
Change5.50%
Shares Out40.85M
Market Cap$31.00M
Enterprise Value$-28.29M
52W Range0.51 - 1.83
Beta-0.40
P/E-0.74
P/B0.54
P/FCF-1.20
EV/EBITDA0.72
EV/FCF1.09
Earnings Yield-134.63%
FCF Yield-83.63%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.15
Current Ratio7.77
Quick Ratio7.77
Revenue 5Y-100.00%
Target$3.00
Target Upside295.26%
Target Median$3.00
Target Range3.00 - 3.00
Volume1.01K
Avg Volume72.84K
EPS Surprise0.22
Investment DNA
How strong this company looks for long-term investors
56
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Positive revenue growth · 275.1%Manageable debt level · 0.15Healthy liquidity · 7.77Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 4 analyst votes · 2026-09-05
88/100
Bullish
Bullish
3
Hold
1
Bearish
0
Price Target
2026-08-07
Low
$3.00
Mean
$3.00
Median
$3.00
High
$3.00
Insider Transactions
Recent executive and insider activity
DAWES KAREN A
Transaction: 06/10/2025
BUY
Change
+20,174
Price
$1.00
Filing
06/11/2025
Type
BUY
Scheeren Joseph
Transaction: 06/10/2025
BUY
Change
+20,174
Price
$1.00
Filing
06/11/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Swirsky Douglas J | OTHER | 0 | Not reported | 05/01/2026 | 05/01/2026 |
| DAWES KAREN A | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Scheeren Joseph | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Phillips Anne M. | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Morgon Pierre A. | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Wright Robin | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Hammacher Alex | BUY | +20,174 | $1.00 | 06/10/2025 | 06/11/2025 |
| Hooftman Leon | BUY | +140,000 | $1.00 | 02/03/2025 | 02/05/2025 |
| Griffiths Graham | BUY | +200,000 | $1.00 | 02/03/2025 | 02/05/2025 |
| Enright William | BUY | +600,000 | $1.00 | 02/03/2025 | 02/05/2025 |
| Brown Gemma | BUY | +160,000 | $1.00 | 02/03/2025 | 02/05/2025 |
| Lynn Geoffrey | OTHER | 0 | Not reported | 12/17/2024 | 12/31/2024 |
| Lynn Geoffrey | OTHER | +24,207 | $3.70 | 12/17/2024 | 12/20/2024 |
| Lynn Geoffrey | OTHER | 0 | Not reported | 12/17/2024 | 12/20/2024 |
| Hooftman Leon | OTHER | 0 | Not reported | 06/03/2024 | 06/18/2024 |
| Hooftman Leon | BUY | +195,166 | $2.00 | 06/03/2024 | 06/18/2024 |
| Wright Robin | BUY | +19,516 | $2.34 | 05/10/2024 | 05/14/2024 |
| Morgon Pierre A. | BUY | +19,516 | $2.34 | 05/10/2024 | 05/14/2024 |
| Hammacher Alex | BUY | +19,516 | $2.34 | 05/10/2024 | 05/14/2024 |
| Phillips Anne M. | BUY | +19,516 | $2.34 | 05/10/2024 | 05/14/2024 |